文献速递消化道肿瘤放疗放疗物理与技术

食管癌根治性放化疗中质子束治疗与调强放疗的疗效比较

Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-06-27

本研究回顾性分析343例接受根治性放化疗的食管癌患者,其中质子束治疗132例、调强放疗211例。质子束治疗组总生存、无进展生存、无远处转移生存均显著优于调强放疗组,且毒性无差异;III期患者5年OS和PFS在质子组更高,但需前瞻性研究确认。

要点

  • 质子束治疗组总生存、无进展生存、无远处转移生存均优于调强放疗组。
  • 两组治疗相关毒性发生率无显著差异。
  • III期患者质子组5年OS和PFS显著更高,I/II期无差异。

核心结论

  • 与调强放疗相比,质子束治疗可能改善食管癌患者的总生存、无进展生存和局部区域无失败生存,尤其局部晚期患者。

研究设计与样本

  • 回顾性单中心分析2007至2014年343例接受根治性放化疗的食管癌患者,质子束治疗132例,调强放疗211例。

主要发现

  • 质子束治疗组总生存优于调强放疗组(P=.011)。
  • 质子束治疗组无进展生存优于调强放疗组(P=.001)。
  • 质子束治疗组无远处转移生存优于调强放疗组(P=.031)。
  • 局部区域无失败生存质子组仅边缘优于调强组(P=.075)。
  • 多因素分析中调强放疗组总生存(HR 1.454;P=.01)、无进展生存(HR 1.562;P=.001)和局部区域无失败生存(HR 1.461;P=.041)均差于质子组。

关键数值与推荐

  • III期患者质子组5年总生存率34.6% vs 25.0%(P=.038)。
  • III期患者质子组5年无进展生存率33.5% vs 13.2%(P=.005)。
  • I/II期患者两组生存无显著差异。
  • 两组治疗相关毒性发生率无显著差异。

临床怎么用

  • 对于局部晚期食管癌,质子束治疗可能作为根治性放化疗的优选放疗技术,但需前瞻性研究验证。

局限性

  • 回顾性单中心设计,年龄和种族因素组间未完全平衡。
  • 结果需前瞻性研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare clinical outcomes between proton beam therapy (PBT) and intensity modulated radiation therapy (IMRT) in patients with esophageal cancer (EC) treated with definitive chemoradiotherapy (CRT). METHODS AND MATERIALS: From 2007 through 2014, 343 EC patients who received definitive CRT with either PBT (n=132) or IMRT (n=211) were retrospectively analyzed. Survival, recurrence, and treatment toxicity were compared between groups. A Cox proportional hazards regression model was performed to test the association between patient/treatment variables and survival. RESULTS: Patient/treatment variables were overall well balanced, except for age and race. Compared with IMRT, PBT had significantly better overall survival (OS; P=.011), progression-free survival (PFS; P=.001), distant metastasis-free survival (DMFS; P=.031), as well as marginally better locoregional failure-free survival (LRFFS; P=.075). No significant differences in rates of treatment-related toxicities were observed between groups. On multivariate analysis, IMRT had worse OS (hazard ratio [HR] 1.454; P=.01), PFS (HR 1.562; P=.001), and LRFFS (HR 1.461; P=.041) than PBT. Subgroup analysis by clinical stage revealed considerably higher 5-year OS (34.6% vs 25.0%, P=.038) and PFS rates (33.5% vs 13.2%, P=.005) in the PBT group for patients with stage III disease. However, no significant intergroup differences in survival were identified for stage I/II patients. CONCLUSIONS: Compared with IMRT, PBT might be associated with improved OS, PFS, and LRFFS, especially in EC patients with locally advanced disease. These results need confirmation by prospective studies.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Xi M, Xu C, Liao Z, et al. Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. Int J Radiat Oncol Biol Phys. 2017. PMID: 29280461. doi:10.1016/j.ijrobp.2017.06.2450

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。